Mandate

Vinge advises Bufab in connection with the listing on NASDAQ OMX Stockholm

February 27, 2014

Vinge advises Bufab in connection with the listing on NASDAQ OMX Stockholm and Nordic Capital Fund V:s offering of shares in connection with the listing. Bufab is a trading company that delivers components and services to the global manufacturing industry. Bufab is a trading company that delivers components and services to the global manufacturing industry. The Company offers its customers a one-stop-shop product offering that covers sourcing, quality assurance and logistics of so called C-Parts, components such as nuts, screws and washers, according to the business model Supply Chain Partner. The Swedish language prospectus was published on 10 February 2014 and the first day of trading was 21 February 2014. The offering attracted strong interest among Swedish and international institutional investors as well as Swedish retail investors. The Offering was over-subscribed multiple times. The final offering price has been set at SEK 46 per share, corresponding to a market value of all shares issued by Bufab of MSEK 1,753.

Vinge’s team consisted of, among others, partners Charlotte Levin, Peter Bäärnhielm and Christina Kokko and associates Jonas Johansson, David Andersson, Mia Örnfeldt, Albert Wållgren and Rikard Lindahl.

Related

Vinge advised Precise Biometrics

Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026